Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China · Delayed Price · Currency is CNY | Market Cap | 58.55B -10.3% |
| Revenue (ttm) | 42.31B +4.9% |
| Net Income | 3.48B +18.9% |
| EPS | 1.31 +19.4% |
| Shares Out | 2.64B |
| PE Ratio | 18.41 |
| Forward PE | 20.02 |
| Dividend | 0.39 (1.64%) |
| Ex-Dividend Date | Jul 27, 2026 |
| Volume | 33,066,396 |
| Open | 23.92 |
| Previous Close | 24.12 |
| Day's Range | 23.88 - 24.86 |
| 52-Week Range | 20.85 - 33.10 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 34.46 (+39.8%) |
| Earnings Date | Aug 26, 2026 |
About SHA:600196
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, car... [Read more]
Financial Performance
In 2025, SHA:600196's revenue was 41.66 billion, an increase of 1.45% compared to the previous year's 41.07 billion. Earnings were 3.37 billion, an increase of 21.69%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for 600196 stock is "Buy." The 12-month stock price target is ¥34.46, which is an increase of 39.80% from the latest price.
News
Shanghai Fosun Pharmaceutical (Group) Quarterly report: Q1 2026
Shanghai Fosun Pharmaceutical (Group) has published its Q1 2026 quarterly earnings report on April 28, 2026.
Shanghai Fosun Pharmaceutical (Group) Annual report: H2 2025
Shanghai Fosun Pharmaceutical (Group) has published its H2 2025 annual report on March 24, 2026.
Shanghai Fosun Pharmaceutical (Group) Slides: H2 2025
Shanghai Fosun Pharmaceutical (Group) has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Shanghai Fosun Pharmaceutical (Group) Quarterly report: Q3 2025
Shanghai Fosun Pharmaceutical (Group) has published its Q3 2025 quarterly earnings report on October 28, 2025.
Shanghai Fosun Pharmaceutical (Group) Slides: Q3 2025
Shanghai Fosun Pharmaceutical (Group) has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.
Shanghai Fosun Pharmaceutical (Group) Quarterly report: H1 2025
Shanghai Fosun Pharmaceutical (Group) has published its H1 2025 quarterly earnings report on August 26, 2025.
Shanghai Fosun Pharmaceutical (Group) Slides: H1 2025
Shanghai Fosun Pharmaceutical (Group) has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 26, 2025.
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Syneos Health partners with Fosun Pharma USA to launch serplulimab
Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One team...
Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech
Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment
China's health-care sector may be next to face regulatory crackdown, says economist
Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...
Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations
Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.